Clinical Trials

Research and Clinical Trials from
Charles Retina Institute

Charles Retina Institute offers a gateway to the frontiers of research and development in the field of retinal care. Pharmaceutial and surgical companies turn to our physicians to serve as primary investigators for their studies in the development of treatments for ocular conditions including macular degeneration, diabetic retinopathy, ocular occlusive diseases, and genetic therapies.

Within the framework of our institute, we have an independent research department that allows us to screen patients for immediate consideration into a multitude of new and innovative therapeutic studies. Patients meeting the required criteria can be enrolled within their first visit.

Current Studies

  • LADDER
    A Phase II, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration. Open to enrollment since July 2016.
    https://clinicaltrials.gov/ct2/show/NCT02510794?term=GX28228&rank=1
  • EXPOSURE
    A Phase II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Exposure-Response Study of Lampalizumab Intravitreal Injections Administered Every Two weeks or Every Four Weeks to Patients with Geographic Atrophy. Open to enrollment since June 2016.
    https://clinicaltrials.gov/ct2/show/NCT02288559?term=GX29455&rank=1
  • PANORAMA
    A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patient with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy.
    Open to enrollment since June 2016.
    https://clinicaltrials.gov/ct2/show/NCT02718326?term=VGFTe-OD-1411&rank=1
  • RUBY
    A Randomized, Double-Masked, Active-Controlled, Multiple-Dose, Phase 2 Study of the Efficacy, Safety and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Diabetic Macular Edema. Open to enrollment since May 2016.
    https://clinicaltrials.gov/ct2/show/NCT02712008?term=REGN910-3&rank=3
  • RAINBOW
    A randomized, controlled study evaluating the efficacy and safety of ranibizumab compared with laser therapy for the treatment of infants born prematurely with retinopathy of prematurity. Phase 3. Open to enrollment since April 2016.
    https://clinicaltrials.gov/ct2/show/NCT02375971?term=rainbow&rank=1
  • BOULEVARD
    A Multiple-Center, Multiple-Dose, Randomized, Active Comparator-Controlled, Double-Masked, Parallel Group, 28-Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficiency of RO6867461 Administered Intravitreally in Patients with Diabetic Macular Edema. Phase 2. Open to enrollment since April 2016.
    https://clinicaltrials.gov/ct2/show/NCT02699450?term=BP30099&rank=1

  • AVENUE
    A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficiency of RO6867461 Administered Intravitreally in Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Phase 2. Open to enrollment since August 2015.
    https://clinicaltrials.gov/ct2/show/NCT02484690?term=BP29647&rank=1
  • CAPELLA
    A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration. Since June 2015. Closed to Enrollment.
    https://clinicaltrials.gov/ct2/show/NCT02418754?term=R2176&rank=1
  • HAWK
    A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration. Phase 3. Closed to Enrollment.
    https://clinicaltrials.gov/ct2/show/NCT02307682?term=RTH258&rank=2
  • SPECTRI
    A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. Phase 3. Closed to Enrollment.
    https://clinicaltrials.gov/ct2/show/NCT02247531?term=GX29185&rank=1
  • ESBA1008 Microvolume Study
    A Prospective, Two-Staged, Single-Masked Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection or Infusion in Subjects With Exudative Age-Related Macular Degeneration. Phase 2. Closed to Enrollment.
    https://clinicaltrials.gov/ct2/show/NCT01849692?term=ESBA&rank=5

For additional information, please contact our study coordinator Melanie Woods at
901-767-4499 or at mwoods@charlesretina.com.